Acalabrutinib has emerged in the field of hematological oncology due to its outstanding clinical performance and unique therapeutic mechanism since its inception.

1、 Drug name

1. Common name: Acalabrutinib

2. Product Name: Calquence ® (Original drug)

3. Dosage form: Capsule

2、 Indications

Akatinib is a Bruton tyrosine kinase (BTK) inhibitor suitable for treating various B-cell hematological malignancies, such as:

1. Mantle cell lymphoma (MCL)

2. Chronic lymphocytic leukemia (CLL)

3. Small lymphocytic lymphoma (SLL)

3、 Specifications and characteristics

1. Specification: 100mg.

2. Characteristic: 100mg capsule.

4、 Main components

Active ingredient: Acatinib.

5、 Usage and dosage

The recommended dosage is usually 100mg per dose, taken orally approximately every 12 hours ¹, until disease progression or unacceptable toxicity occurs. It needs to be swallowed whole with water and can be taken with or without food.

6、 Dose adjustment

For patients with specific adverse reactions (such as infection, bleeding, decreased blood cells, arrhythmia), treatment should be interrupted, dosage reduced, or permanently discontinued. The specific adjustment plan should follow clinical guidelines and doctor guidance.

7、 Medication precautions

1. Medication method: Swallow the whole capsule, do not open, chew or dissolve the contents of the capsule.

2. Diet: Can be taken with or without food.

3. Missed dose: If one dose is missed, the regular dose should be taken at the next scheduled time and no additional dose should be taken.

4. Vomiting: If vomiting occurs after taking medication, additional doses should not be taken, and the regular dose should be taken at the next scheduled time.

8、 Medication for special populations

Pregnant women, lactating women, children, the elderly, and patients with liver and kidney dysfunction should be used with special caution and strictly follow medical advice. Doctors will conduct benefit risk assessments based on specific circumstances and may adjust the dosage.

9、 Adverse reactions

Common adverse reactions include headache, diarrhea, musculoskeletal pain, rash, bleeding, infections (such as respiratory infections), and decreased blood cell count (such as neutropenia). More serious side effects may also occur, such as severe infections, arrhythmia, etc.

10、 Contraindications

Patients known to have severe allergic reactions to acatinib or any excipients are prohibited from using it.

11、 Drug interactions

Simultaneous use with potent CYP3A inhibitors or inducers may affect the blood concentration of acatinib, and should be avoided or the dosage adjusted under the guidance of a doctor. Anticoagulants and antiplatelet drugs may increase the risk of bleeding.

12、 Storage method

It is usually recommended to store at room temperature of 20 ° C to 25 ° C (68 ° F to 77 ° F). Should be stored in the original container and protected from moisture.

Acalabrutinibinformation